Search
NASH - Nonalcoholic Steatohepatitis Clinical Trials in Indianapolis, IN
A listing of 5 NASH - Nonalcoholic Steatohepatitis clinical trials in Indianapolis, IN actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 5 of 5
The city of Indianapolis, Indiana, currently has 5 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
RSV Vaccine For Adults With Kidney, Liver or Lung Transplant
Recruiting
The RSVoice Trial is a Phase 3 clinical trial conducted by Moderna to evaluate the safety and immune response of an investigational vaccine aimed at preventing respiratory syncytial virus (RSV) infection in adults who have received a kidney, liver, or lung transplant.
Conditions:
Kidney Transplantation
Kidney Transplant
Liver Transplantation
Lung Transplantation
Chronic Kidney Disease
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Overweight Trials
Recruiting
Overweight trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Overweight
Featured Trial
Low back pain Trials
Recruiting
Low back pain trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Low back pain
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Recruiting
This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks. Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Nonalcoholic Fatty Liver Disease in HIV Database
Recruiting
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD encompasses simple nonalcoholic steatosis (nonalcoholic fatty liver [NAFL]) and nonalcoholic steatohepatitis (NASH) in which there is evidence of hepatocellular injury and/or fibrosis. NAFLD is the most common liver disease in adults and the second lea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: NASH - Nonalcoholic Steatohepatitis
Tocotrienol Against the Progression of End Stage Liver Disease
Recruiting
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis. The study is double blind and participants will be randomized to take 2 capsules of TCT (200mg) or placebo twice a day for 3 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: IU Health Unviersity Hospital, Indianapolis, Indiana
Conditions: End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Indiana University (IU) School of Medicine, Indianapolis, Indiana
Conditions: Non Alcoholic Steatohepatitis (NASH)
1 - 5 of 5